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ABSTRACTSbetween February 2007 and June 2008. Pre and postoperative histology
was compared and analysed for the reoperation rate.
Results: 33 patients were conﬁrmed to have pure IDC on postoperative
histology, but in 44 (57%) ductal carcinoma in-situ (DCIS) was also
reported.
Conclusions: Reoperation following breast conserving surgery was higher
when in-situ disease was unexpectedly identiﬁed postoperatively. Dis-
cussion with breast histopathologists reveals that not all would report the
presence of in-situ disease in a core biopsy containing mainly invasive
carcinoma. We recommend a standard proforma for preoperative core
biopsy reports to include both invasive and in-situ components.
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1081: DUAL ASSESSMENT INSTEAD OF THE TRIPLE ASSESSMENT FOR
UNDER 25S: TIME FOR A CHANGE IN BREAST CLINIC PRACTICE?
Asad Parvaiz, Tapan Sircar. New Cross Hospital, Wolverhampton, UK.
Aims: According to ABS guidelines for the patients under the age of 25
years, solid breast lesions may be safely diagnosed using clinical and im-
aging information and do not require needle biopsy. We aimed to study
our practice in this group.
Methods: All patients up to the age of 25 years having a needle biopsy
between Jun 2009 and Nov 2012 were included. Their clinical ﬁndings,
ultrasound features and biopsy results were recorded.
Results:100patientswere identiﬁed(94womenand6men).Medianagewas
21 years (range 15-25). 71 patients had ultrasound categoryU1-2 and they all
had benign histology on needle core biopsy. 25 patients had U3 lesions; 1
patient amongst themhad cancer. 4 patients did not needultrasonogramand
had benign pathologies. No patient had ultrasound U4-5 categories.
Conclusions: In patients up to the age of 25 years, needle biopsy can be
avoided if they have normal/benign clinical examination (P1-2) and
normal/benign ultrasound ﬁndings (U1-2). In our study 71% of patients
could have avoided needle biopsies. Reducing the number of biopsies in
this group will minimize patient distress, reduce NHS costs and also free
up breast services to provide quality care to cancer patients.
1104: SURGICAL TREATMENT OF FRAGMENTED FOCAL BREAST TU-
MOURS IN RESPONSE TO NEOADJUVANT CHEMOTHERAPY
Sanad Hadidi. King's College London, London, UK.
Aim: This study aimed primarily to determinewhether the fragmentation of
tumours onMRI can inﬂuence the surgical decision. Its secondary aimwas to
analyse the features of fragmented tumours versus non-fragmented tumours
after treatment with NAC on both MRI and post-surgical pathology
Methods: The data was retrospectively analysed using prospectively
collected data. Breast cancer patients who had been diagnosed between
2005-2010 and treated with NAC were reviewed (166 patient records) at
the Leeds General Inﬁrmary.
Results: The MRI scans have shown that the median baseline and ﬁnal size
of fragmented tumours were 45 mm and 27 mm, respectively, whereas
median baseline and ﬁnal size of non-fragmented tumours were 35 mm
and 14.5 mm, respectively.
A spearman rank correlation of 0.8 was found between the size of the
fragmented tumours measured on pathology versus MRI, whereas non-
fragmented tumours showed a weaker correlation.
Conclusion: Fragmentation of focal breast tumour did not affect the initial
planned surgery. Moreover, there was a strong correlation between the
size of the fragmented tumour measured on pathology versus MRI.
Furthermore, fragmented tumours tend to have a larger median overall
size on both baseline and ﬁnal MRI than non-fragmented tumours, which
might potentially affect the initial surgical procedure plan.
1188: INTER-HOSPITAL DIFFERENCES IN STANDARDS OF CARE OF
ELDERLY PATIENTS WITH PRIMARY BREAST CANCER
Hirah Rizki 1, Hannah Rizki 3, N. Garg 1, Caroline Mortimer 2. 1 Ipswich
Hospital, Ipswich, UK; 2Anglia Cancer Network, East Anglia, UK; 3 London
School of Economics, London, UK.
Aim: Published literature from an elderly cohort of patients with primary
breast cancer showed inter-hospital differences in standards of care across
East Anglia (Wishart 2009). Thiswas attributed to variation in surgery, lymph
node (LN) sampling and assessmentof estrogen receptor (ER) status betweenhospitals. Since then,wehave seen thedevelopmentof specialist breastunits,
multidisciplinary decision making and regional policies. We aimed to assess
whether these developments reduced inter-hospital differences.
Methods: We reviewed clinical details of 657 patients over 70 with pri-
mary breast cancer from eight units across East Anglia between 1st April to
30 September in 2010 and 2011. Data was analysed using chi-squared
statistical test.
Results: The percentage of patients offered surgery from each hospital
ranged between 59% and 82% (p¼0.02). LN status was assessed in 95% of
patients with 8% variation across the region (range 92 - 100%). ER status
was known in 96% of patients (range 83-100%).
Conclusions: We identiﬁed a signiﬁcant variation in patients offered sur-
gery across the region, however, this is much lower than seen previously.
We have also observed improved LN and ER testing. The improvements
may be attributable to the advent of regional network policies leading to
standardised practice.
1210: THE APPROPRIATENESS OF PRE-OPERATIVE BLOOD TESTS AT A
DISTRICT GENERAL HOSPITAL BREAST SURGERY DEPARTMENT
Rashad Jurangpathy, Annakan Navaratnam, Arunmoy Chakravorty,
Sankaran Chandrasekharan. Breast Surgery Department, Colchester General
Hospital, Colchester, UK.
Background: Pre-operative blood tests are routinely ordered when
assessing a patient's ﬁtness for surgery. These investigations can help
reduce patient mortality and morbidity from surgery but often are of little
clinical use especially for short, low risk operations such as wide local
excisions in Breast Surgery. The practice of routine pre-operative blood
tests was reviewed in a District General Hospital Breast Surgery
Department.
Methods: A retrospective study of all pre-operative blood tests conducted
for patients having breast surgery at Colchester General Hospital between
1st August 2011 and 31st December 2011 was undertaken. ‘Appropriate-
ness' of blood tests were evaluated according to NICE guidance criteria
based on age, grade of surgery and ASA grade.
Results: 766 blood tests were performed on 185 patients in this ﬁvemonth
period. 432 (56.4%) blood tests were deemed ‘inappropriate' according to
NICE guidance. Approximately, £3010 was spent on such inappropriate
tests during this time period.
Conclusions: A large number of unnecessary pre-operative blood tests are
requested without clinical indication leading to wasted resources and an
unjustiﬁed expense to the hospital Trust. Following this quality improve-
ment project, we have implemented guidelines on pre-operative blood
tests within the department that have since reduced the number of
‘inappropriate' tests.
1262: PREDICTING ADDITIONAL POSITIVE NON-SENTINEL LYMPH
NODES AFTER MACROMETASTASIS AT SENTINEL LYMPH NODE BIOPSY
e IT'S A NUMBERS GAME
Robert Milligan, Helen Hawkins, Magdi Youssef, Michael Carr. Wansbeck
General Hospital, Ashington, UK.
Aim: To Use the validated MD Anderson Cancer Center Nomogram to
retrospectively predict additional positive non-sentinel lymph nodes in
patients who underwent positive SLNB with macrometastasis.
Methods: Data was collected retrospectively regarding 225 consecutive
patients who underwent SLNB across two hospitals within an NHS Trust
over a two year period (2010 and 2011). Age, sex tumour size and
type and nodal status at SLNB and subsequent ALND were recorded.
Results:33/36 patients with postive SLNB underwent ALND, of which only
7(21.2%) were positive. 1/8(12.5%) patients had further positive nodes at
ALND where predicted positive additional nodes was low (0-29%). 2/
19(10.5%) patients with moderate risk (30-59%) had additional positive
nodes. 4/6(66.7%) patients with a high risk of additional positive nodes
(60-89%) had further positive nodes at ALND.
Conclusion: The MD Anderson Cancer Center Nomogram may be used as
an adjunct in calculating the beneﬁt of ALND in certain patient groups; it
appears accurate for high and low risk patients but over-estimated pa-
tients with moderate risk of further axillary disease. Where axillary con-
servation is considered, patients must have all available information to
allow an informed decision; nomograms may improve patient knowledge
of risk of further axillary disease.
